Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 95, Issue 6, 1997, Pages 331-334

  Filippi, M ^a,c   Yousry, T ^b   Rocca, M A ^a   Fesl, G ^b   Voltz, R ^b   Comi, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Delayed scanning; Gadolinium DTPA; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE COURSE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; REMISSION;

EID: 0030856562     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1997.tb00220.x     Document Type: Article

References (16)

1. MILLER DH, BARKHOF F, BERRY I, KAPPOS L, SCOTTI G, THOMPSON AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 1991: 54: 683-8.
2. MILLER DH, BARKHOF F, NAUTA JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993: 116: 1077-94.
3. HAUSTEIN J, LANIADO M, NIENDORF HP et al. Triple-dose versus single-dose gadopentetate dimeglumine: a randomised study of 199 patients. Radiology 1993: 186: 855-60.
4. WOLANSKI LJ, BARDINI JA, COOK SD, ZIMMER AE, SHEFFET A, LEE HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994: 4: 141-5.
5. FILIPPI M, CAMPI A, MARTINELLI V et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995: 59: 540-4.
6. FILIPPI M, YOUSRY T, CAMPI A et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with multiple sclerosis. Neurology 1996: 46: 379-84.
7. FILIPPI M, CAPRA R, CAMPI A et al. Triple dose of gadolinium-DTPA and delayed scanning in benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996: 60: 526-30.
8. FINELLI DA, HURST GC, GULLAPALI RP, BELLON EM. Improved contrast of enhancing brain lesions on post-gadolinium T1 weighted spin-echo images with use of magnetization transfer. Radiology 1994: 36: 62-7.
9. METHA RC, PIKE BG, ENZMANN R. Improved detection of enhancing and non-enhancing lesions of multiple sclerosis with magnetization transfer. Am J Neuroradiol 1995: 16: 1771-8.
10. KERMODE AG, TOFTS PS, THOMPSON AJ et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990: 40: 229-35.
11. TOFTS PS, KERMODE AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Fundamental concepts. Magn Reson Med 1991: 17: 357-67.
12. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983: 13: 227-31.
13. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983: 33: 1444-52.
14. VINUELA FV, FOX AJ, DEBRUN GM, FEASBY TE, EBERS GC. New perspectives in computed tomography of multiple sclerosis. Am J Neuroradiol 1982: 3: 277-81.
15. SEARS S, MCCAMMON A, BIGELOW R, HAYMAN LA. Maximizing the harvest of contrast enhancing lesions in multiple sclerosis. Neurology 1982: 32: 815-20.
16. SPIEGEL SM, VINUELA F, FOX AJ, PELZ DM. CT of multiple sclerosis: reassessment of delayed scanning with high doses of contrast material. Am J Roentgenol 1985: 145: 497-500.